AZ licences Movantik rights to RedHill
AstraZeneca has completed its deal to sublicense certain rights to Movantik to RedHill Biopharma
Read More
Tag: Movantik
AZ divests Movantik rights to RedHill
The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
